New research supports the use of highly effective therapies as first-line treatment in children with relapsing-remitting pediatric-onset multiple sclerosis.
/PRNewswire/ Heligenics, Inc., a pioneering biotechnology company applying functional genomics to drug discovery, announced today that it has reshaped the.
Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the resulting entity will continue the business of Atriva Therapeutics. Shareholders of Atriva will receive not less than 75% of the securities of the resulting issuer, with the current shareholders of Biocure Technology holding the remainder. The transaction is subject to various terms and conditions, including